From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA permits RegeneRx licensee to conduct phase 3 trial for epidermolysis bullosa

from Healio

RegeneRx Biopharmaceuticals announced in a press release that GtreeBNT Co., Ltd., has received a positive response from the FDA for a phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa. RGN-137 has Thymosin beta 4 as an inactive pharmaceutical ingredient in a dermal wound healing gel, according to RegeneRx, a clinical-stage drug development company. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063